## lung and chest tumours

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v1 \)

## gastrointestinal cancers

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v28 \)

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v38 \)

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v50 \)

## genitourinary cancers

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v58 \)

## haematological malignancies

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v69 \)

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v83 \)

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  \( v91 \)

## hereditary syndromes

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening  \( v103 \)

## supportive and palliative care

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines  \( v111 \)

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients  \( v119 \)

## appendices

Appendix 1  \( v134 \)

Appendix 2  \( v136 \)

Appendix 3  \( v138 \)

Appendix 4  \( v140 \)

Appendix 5  \( v142 \)

Appendix 6  \( v143 \)

Appendix 7  \( v145 \)

Appendix 8  \( v146 \)

## corrigendum

ESMO Guidelines Committee Disclosures  \( v149 \)